How many biosimilars have been approved in the United States?
What are the biosimilars for Avastin, Enbrel, Epogen, Herceptin, Humira, Lantus, Lucentis, Neulasta, Neupogen, Remicade, and Rituxan? List of all biosimilars approved in the United States.
The are currently 40 approved biosimilars approved by the FDA (Food and Drug Administration). The most recent biosimilar approval was Idacio (adalimumab-aacf) on December 13, 2022.
What is a Biosimilar?
According the to FDA, a biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from an existing FDA-approved reference product.
Biological products are a diverse category of products, and include therapeutic proteins (example filgrastim) and monoclonal antibodies (example adalimumab). Biological products are generally large, complex molecules, and inherent variations are normal and expected within the manufacturing process.
A manufacturer developing a biosimilar will need to demonstrate that its product is highly similar to the characteristics of the reference product in terms of purity, chemical identity, and bioactivity. The manufacturer must also demonstrate that its product has no clinically meaningful differences to the reference product in terms of safety, purity, and potency (safety and effectiveness) which is determined though human pharmacokinetic and pharmacodynamic studies, and additional clinical studies if needed.
Biosimilar products can only be dispensed in place of another biological product if the health care provider specifically prescribes the biosimilar product by name.
What is an Interchangeable?
An interchangeable product is a biological product that meets all the requirements for a biosimilar product, but also meets additional requirements outlined by the Biologics Price Competition and Innovation Act.
A manufacturer developing an interchangeable product will need to demonstrate that its product is expected to produce the same clinical result as the reference product in any given patient. If a product is to be administered to a patient more than once, the risk in terms of safety and reduced efficacy of switching back and forth between an interchangeable product and a reference product will need to have been evaluated.
Interchangeable products may be substituted at pharmacy-level without the intervention of the health care provider who prescribed the reference product. A health care provider also can prescribe an interchangeable product just like they would prescribe a biosimilar or a reference product. (Note that pharmacy laws and practices vary from state to state.)
Learn about cost-savings, clinical use, and safety of biosimilars.
Biosimilars by reference product (or by approval date)
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Vegzelma (bevacizumab-adcd) |
Biosimilar | Celltrion, Inc. | September 27, 2022 |
Alymsys (bevacizumab-maly) |
Biosimilar | Amneal Pharmaceuticals, Inc. | April 13, 2022 |
Zirabev (bevacizumab-bvzr) |
Biosimilar | Pfizer Inc. | June 27, 2019 |
Mvasi (bevacizumab-awwb) |
Biosimilar | Amgen Inc. | September 14, 2017 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Eticovo (etanercept-ykro) |
Biosimilar | Samsung Bioepis Co., Ltd. | April 25, 2019 |
Erelzi (etanercept-szzs) |
Biosimilar | Sandoz Inc. | August 30, 2016 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Retacrit (epoetin alfa-epbx) |
Biosimilar | Hospira Inc. | May 15, 2018 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Kanjinti (trastuzumab-anns) |
Biosimilar | Amgen Inc. | June 13, 2019 |
Trazimera (trastuzumab-qyyp) |
Biosimilar | Pfizer Inc. | March 11, 2019 |
Ontruzant (trastuzumab-dttb) |
Biosimilar | Samsung Bioepis Co., Ltd. | January 18, 2019 |
Herzuma (trastuzumab-pkrb) |
Biosimilar | Celltrion, Inc. | December 14, 2018 |
Ogivri (trastuzumab-dkst) |
Biosimilar | Mylan GmbH | December 1, 2017 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Idacio (adalimumab-aacf) |
Biosimilar | Fresenius Kabi | December 13, 2022 |
Yusimry (adalimumab-aqvh) |
Biosimilar | Coherus BioSciences, Inc. | December 17, 2021 |
Hulio (adalimumab-fkjp) |
Biosimilar | Mylan Pharmaceuticals Inc. | July 6, 2020 |
Abrilada (adalimumab-afzb) |
Biosimilar | Pfizer Inc. | November 15, 2019 |
Hadlima (adalimumab-bwwd) |
Biosimilar | Samsung Bioepis Co., Ltd. | July 23, 2019 |
Hyrimoz (adalimumab-adaz) |
Biosimilar | Sandoz Inc. | October 30, 2018 |
Cyltezo (adalimumab-adbm) |
Interchangeable | Boehringer Ingelheim Pharmaceuticals, Inc. | August 25, 2017 |
Amjevita (adalimumab-atto) |
Biosimilar | Amgen Inc. | September 23, 2016 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Rezvoglar (insulin glargine-aglr) |
Interchangeable | Eli Lilly and Company | December 17, 2021 |
Semglee (insulin glargine-yfgn) |
Interchangeable | Mylan Pharmaceuticals Inc. | July 28, 2021 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Cimerli (ranibizumab-eqrn) |
Interchangeable | Coherus BioSciences, Inc. | August 2, 2022 |
Byooviz (ranibizumab-nuna) |
Biosimilar | Samsung Bioepis Co., Ltd. | September 17, 2021 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Stimufend (pegfilgrastim-fpgk) |
Biosimilar | Fresenius Kabi USA, LLC | September 1, 2022 |
Fylnetra (pegfilgrastim-pbbk) |
Biosimilar | Amneal Pharmaceuticals, Inc. | May 26, 2022 |
Nyvepria (pegfilgrastim-apgf) |
Biosimilar | Pfizer Inc. | June 10, 2020 |
Ziextenzo (pegfilgrastim-bmez) |
Biosimilar | Sandoz Inc. | November 4, 2019 |
Udenyca (pegfilgrastim-cbqv) |
Biosimilar | Coherus BioSciences, Inc. | November 2, 2018 |
Fulphila (pegfilgrastim-jmdb) |
Biosimilar | Mylan N.V. | June 4, 2018 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Releuko (filgrastim-ayow) |
Biosimilar | Kashiv BioSciences, LLC | February 25, 2022 |
Nivestym (filgrastim-aafi) |
Biosimilar | Pfizer Inc. | July 20, 2018 |
Zarxio (filgrastim-sndz) |
Biosimilar | Sandoz Inc. | March 6, 2015 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Avsola (infliximab-axxq) |
Biosimilar | Amgen Inc. | December 6, 2019 |
Ixifi (infliximab-qbtx) |
Biosimilar | Pfizer Inc. | December 13, 2017 |
Renflexis (infliximab-abda) |
Biosimilar | Samsung Bioepis Co., Ltd. | April 21, 2017 |
Inflectra (infliximab-dyyb) |
Biosimilar | Celltrion, Inc. | April 5, 2016 |
Name | Regulatory Designation | Company Name | FDA Approved |
---|---|---|---|
Riabni (rituximab-arrx) |
Biosimilar | Amgen Inc. | December 17, 2020 |
Ruxience (rituximab-pvvr) |
Biosimilar | Pfizer Inc. | July 23, 2019 |
Truxima (rituximab-abbs) |
Biosimilar | Celltrion, Inc. | November 28, 2018 |
Biosimilars by approval date
- Idacio (adalimumab-aacf) - December 13, 2022
- Vegzelma (bevacizumab-adcd) - September 27, 2022
- Stimufend (pegfilgrastim-fpgk) - September 1, 2022
- Cimerli (ranibizumab-eqrn) - August 2, 2022
- Fylnetra (pegfilgrastim-pbbk) - May 26, 2022
- Alymsys (bevacizumab-maly) - April 13, 2022
- Releuko (filgrastim-ayow) - February 25, 2022
- Yusimry (adalimumab-aqvh) - December 17, 2021
- Rezvoglar (insulin glargine-aglr) - December 17, 2021
- Byooviz (ranibizumab-nuna) - September 17, 2021
- Semglee (insulin glargine-yfgn) - July 28, 2021
- Riabni (rituximab-arrx) - December 17, 2020
- Hulio (adalimumab-fkjp) - July 6, 2020
- Nyvepria (pegfilgrastim-apgf) - June 10, 2020
- Avsola (infliximab-axxq) - December 6, 2019
- Abrilada (adalimumab-afzb) - November 15, 2019
- Ziextenzo (pegfilgrastim-bmez) - November 4, 2019
- Hadlima (adalimumab-bwwd) - July 23, 2019
- Ruxience (rituximab-pvvr) - July 23, 2019
- Zirabev (bevacizumab-bvzr) - June 27, 2019
- Kanjinti (trastuzumab-anns) - June 13, 2019
- Eticovo (etanercept-ykro) - April 25, 2019
- Trazimera (trastuzumab-qyyp) - March 11, 2019
- Ontruzant (trastuzumab-dttb) - January 18, 2019
- Herzuma (trastuzumab-pkrb) - December 14, 2018
- Truxima (rituximab-abbs) - November 28, 2018
- Udenyca (pegfilgrastim-cbqv) - November 2, 2018
- Hyrimoz (adalimumab-adaz) - October 30, 2018
- Nivestym (filgrastim-aafi) - July 20, 2018
- Fulphila (pegfilgrastim-jmdb) - June 4, 2018
- Retacrit (epoetin alfa-epbx) - May 15, 2018
- Ixifi (infliximab-qbtx) - December 13, 2017
- Ogivri (trastuzumab-dkst) - December 1, 2017
- Mvasi (bevacizumab-awwb) - September 14, 2017
- Cyltezo (adalimumab-adbm) - August 25, 2017
- Renflexis (infliximab-abda) - April 21, 2017
- Amjevita (adalimumab-atto) - September 23, 2016
- Erelzi (etanercept-szzs) - August 30, 2016
- Inflectra (infliximab-dyyb) - April 5, 2016
- Zarxio (filgrastim-sndz) - March 6, 2015
Related medical questions
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- Can Enbrel be taken with antibiotics?
- Can you take Enbrel with a cold?
- What are the new drugs for the treatment of plaque psoriasis?
- How long does it take for Enbrel to work?
- How long can Enbrel be left unrefrigerated?
- How and where do you inject Enbrel?
- Does perispinal etanercept work for stroke recovery?
- Do Enbrel injections hurt?
- What is the difference between Erelzi and Enbrel?
- What happens when you stop taking Humira?
Related support groups
- Enbrel (20 questions, 208 members)
- Etanercept (9 questions, 8 members)
- Humira (64 questions, 361 members)
- Lantus (44 questions, 112 members)
- Remicade (21 questions, 184 members)
- Rituxan (17 questions, 101 members)
- Neulasta (17 questions, 27 members)
- Herceptin (15 questions, 29 members)
- Pegfilgrastim (13 questions, 4 members)
- Trastuzumab (12 questions, 4 members)
- Adalimumab (11 questions, 13 members)
- Rituximab (10 questions, 51 members)
- Infliximab (7 questions, 16 members)
- Amjevita (5 questions, 5 members)
- Fulphila (5 questions, 3 members)
- Avastin (5 questions, 44 members)
- Avsola (4 questions, 3 members)
- Udenyca (4 questions, 4 members)
- Renflexis (4 questions, 3 members)
- Inflectra (4 questions, 7 members)
- Ixifi (4 questions, 3 members)
- Cyltezo (4 questions, 3 members)
- Erelzi (4 questions, 4 members)
- Hyrimoz (3 questions, 4 members)
- Retacrit (3 questions, 4 members)
- Hulio (3 questions, 3 members)
- Lucentis (3 questions, 16 members)
- Filgrastim (3 questions, 5 members)
- Bevacizumab (3 questions, 7 members)
- Eticovo (3 questions, 3 members)
- Mvasi (2 questions, 4 members)
- Neupogen (2 questions, 15 members)
- Zarxio (2 questions, 5 members)
- Epogen (2 questions, 10 members)
- Ogivri (2 questions, 3 members)
- Procrit (2 questions, 14 members)
- Truxima (2 questions, 3 members)
- Nivestym (2 questions, 3 members)
- Herzuma (2 questions, 3 members)
- Yusimry (1 questions, 3 members)
- Epoetin Alfa (1 questions, 3 members)
- Zirabev (1 questions, 3 members)
- Fylnetra (1 questions, 3 members)
- Ontruzant (1 questions, 3 members)
- Rezvoglar (1 questions, 3 members)
- Riabni (1 questions, 3 members)
- Nyvepria (1 questions, 3 members)
- Ziextenzo (1 questions, 3 members)
- Trazimera (1 questions, 3 members)
- Releuko (1 questions, 3 members)
- Byooviz (1 questions, 3 members)
- Semglee (1 questions, 3 members)
- Abrilada (1 questions, 3 members)
- Alymsys (1 questions, 3 members)